COMP <GO>
PALI vs ARTV // 10Y YIELD & FRED MACRO BETA
Palisade Bio Inc. (NASDAQ) VS. Artiva Biotherapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PALI 2
— ARTV 0
■ METRIC PARITY
LAST: $1.16 (-2.52%) • MKT CAP: $207.4M
macro-sensitivity
—
LAST: $4.19 (-0.95%) • MKT CAP: $206.8M
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PALI VS. ARTV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PALI | ARTV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.23% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 1.03 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.1 | 20.6 | +9.49 | PALI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $207.4M | $206.8M | $576.8K | PALI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PALI REV | ARTV REV | PALI GROSS % | ARTV GROSS % | PALI FCF | ARTV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$10.8M | -$79.3M |
| FY 2024 | $0 | $251.0K | — | — | -$12.2M | -$55.7M |
| FY 2023 | $250.0K | $32.9M | — | — | -$11.1M | -$47.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PALI // BETA —
ARTV // BETA —